For this purpose, we estimated the binding capacity of the tested MM-compounds to a multitude of molecular targets with established roles in cancer: ABL1, ABL2, AKT1, AKT2, AKT3, BCR, BTK, CA-IX, CA-XII, CDK2, CDK4, CDK6, CDK7, ICAM-1, mTOR, mTOR2, and PD-L1. This evidence concerns the gene CDK4 and cancer.